Skip to content
Screener

Jazz Pharmaceuticals JAZZ Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$1.0BMiss by $1.5M
EPS-$8.25Miss by $2.13
Revenue estimate$1.0B
EPS estimate-$6.12

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$1.2B
EPS estimate$6.47

Financials

Q2 2025

Income statement

See full
Revenue$1.0B+2.1%
Operating income-$686.4M-444%
Net income-$718.5M-526%
EPS (diluted)-$11.74-571%

Balance sheet

See full
Cash & equivalents$1.2B-12.2%
Total debt$5.4B-6.2%
Total equity$3.7B-1.5%
Total assets$10.9B-3.7%

Cash flow

See full
Operating cash flow$88.8M-73.2%
CapEx$12.9M+82.6%
Free cash flow$75.9M-76.6%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$6.54B-2.0%
Enterprise value$10.77B-2.9%
P/S1.6×-0.1×

Profitability

See full
Operating margin-7.1%-21.5pp
Net margin-9.9%-20.0pp
FCF margin31%+4.2pp

Returns & leverage

See full
Return on equity-10.8%-21.7pp
Debt / equity1.5×-0.1×
Current ratio1.6×-0.7×

Segments

By product

See full
Xywav$415.3M+12.7%
Epidiolex/Epidyolex$251.7M+1.9%
Rylaze/Enrylaze$100.7M-6.6%
Zepzelca$74.5M-8.0%
High-sodium oxybate AG royalty revenue$54.1M0.0%

By geography

See full
Europe$82.8M+0.7%
All other$26.7M+56.2%

FAQ

When did Jazz Pharmaceuticals report Q2 2025 earnings?
Jazz Pharmaceuticals (JAZZ) reported Q2 2025 earnings on August 5, 2025 after market close.
What were Jazz Pharmaceuticals's Q2 2025 revenue and EPS?
Jazz Pharmaceuticals reported revenue of $1.0B and eps of $-8.25 for Q2 2025.
Did Jazz Pharmaceuticals beat estimates in Q2 2025?
Revenue missed the consensus estimate of $1.0B by $1.5M. EPS missed the consensus estimate of $-6.12 by $2.13.
How did Jazz Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.1% from $1.0B a year earlier.
Where can I find Jazz Pharmaceuticals's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001232524-25-000061) and the 10-Q periodic report (0001232524-25-000063) directly on SEC EDGAR. The filing index links above go to sec.gov.